What's better than momentum? Mo' momentum.
Let's take a closer look at five of this past week's biggest scorchers.
|April 20||Weekly Gain||My Watchlist|
Human Genome Sciences
Human Genome Sciences doubled after rebuffing an unsolicited buyout offer. Even though it was a longtime partner of the company with the surprise bid, Human Genome Sciences wants to see if anyone else is willing to raise the offer of $13 a share that it turned down.
Endocyte nearly doubled after striking a licensing deal with Merck for its lead cancer-tackling product, vintafolide.
Stratasys climbed after the maker of 3-D printers moved to acquire privately held Israeli peer Objet. The combination will make Statasys a bigger player in the expensive but promising realm of 3-D printing.
Vringo soared 30% after a filing revealed that Mark Cuban acquired a 7.4% stake in the company. Vringo is a small app maker that generated just $714,000 in revenue last year. However, last month it struck a deal to merge with a company that holds a few patents from former dot-com darling Lycos.
Sequenom moved higher after announcing an agreement with health care cost-management provider MultiPlan to offer its genetic analysis test for pregnant women at increased risk for fetal aneuploidy.
More winners for you
It was a great week for these five stocks. If you want to get an early read on some of tomorrow's major gainers, here's a special report on three hidden winners in a booming industry. The report is free -- like this article -- but it won't be around forever, so check it out now.
Motley Fool newsletter services have recommended buying shares of Stratasys. The Motley Fool has a disclosure policy. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. Try any of our Foolish newsletter services free for 30 days.
Longtime Fool contributor Rick Munarriz calls them as he sees them. He does not own shares in any of the stocks in this story. Rick is also part of the Rule Breakers newsletter research team, seeking out tomorrow's ultimate growth stocks a day early.